• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mass. Supremes: Pharma Cos. liable for generic labeling issues

March 19, 2018 By Fink Densford

Merck

Merck (NYSE:MRK) and other large brand-name pharmaceutical manufacturers could be legally liable for injuries resulting not from the use of their brand name products, but from generic versions of those drugs made by other companies, according to a new ruling from the Massachusetts Supreme Judicial Court.

The court ruling could set the precedent that such brand-name pharma companies could be found liable for reckless behavior if they fail to update labeling for their products which are also used for generic versions, according to court documents.

In the case, plaintiff Brian Rafferty claimed labeling on a generic version of Merck’s Provacar failed to indicate that sexual side affects he experienced could last even after he had stopped taking the drug.

Rafferty was forced to level the suit against Merck due to a ruling in 2011 from the US Supreme Court that set a precedent that generic drug companies couldn’t be sued for label warning issues related to side effects, as the generic producers are required to use the name-brand producer’s label on their products.

Rafferty’s case was dismissed by a lower court, but a higher court reversed the decision and allowed for a recklessness suit in place of negligence, according to a Reuters report.

“Where a brand-name drug manufacturer provides an inadequate warning for its own product, it knows or should know that it puts at risk not only the users of its own product, but also the users of the generic product. Consequently, this is the rare (perhaps the only) type of case involving a manufactured product where the requirements of general negligence may be satisfied even where the requirements of products liability are not,” Massachusetts Supreme Court Chief Justice Ralph Gants wrote.

Merck said that it was disappointed by the decision but stands by its Proscar product, according to the Reuters report.

Filed Under: Business/Financial News, Featured, Legal News, Pharmaceuticals Tagged With: Merck

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS